Diagnosis and Treatment of Non-24-h Sleep-Wake Disorder in the Blind
- PMID: 28229310
- DOI: 10.1007/s40265-017-0707-3
Diagnosis and Treatment of Non-24-h Sleep-Wake Disorder in the Blind
Abstract
Non-24-h sleep-wake disorder (non-24) is a circadian rhythm disorder occurring in 55-70% of totally blind individuals (those lacking conscious light perception) in which the 24-h biological clock (central, hypothalamic, circadian pacemaker) is no longer synchronized, or entrained, to the 24-h day. Instead, the overt rhythms controlled by the biological clock gradually shift progressively earlier or later (free run) in accordance with the clock's near-24-h period, resulting in a recurrent pattern of daytime hypersomnolence and night-time insomnia. Orally administered melatonin and the melatonin agonist tasimelteon have been shown to entrain (synchronize) the circadian clock, resulting in improvements in night-time sleep and daytime alertness. We review the basic principles of circadian rhythms necessary to understand and treat non-24. The time of melatonin or tasimelteon administration must be considered carefully. For most individuals, those with circadian periods longer than 24 h, low-dose melatonin should be administered about 6 h before the desired bedtime, while in a minority, those with circadian periods shorter than 24 h (more commonly female individuals and African-Americans), melatonin should be administered at the desired wake time. Small doses (e.g., 0.5 mg of melatonin) that are not soporific would thus be preferable. Administration of melatonin or tasimelteon at bedtime will entrain individuals with non-24 but at an abnormally late time, resulting in continued problems with sleep and alertness. To date, tasimelteon has only been administered 1 h before the target bedtime in patients with non-24. Issues of cost, dose accuracy, and purity may figure into the decision of whether tasimelteon or melatonin is chosen to treat non-24. However, there are no head-to-head studies comparing efficacy, and studies to date show comparable rates of treatment success (entrainment).
Similar articles
-
Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials.Lancet. 2015 Oct 31;386(10005):1754-64. doi: 10.1016/S0140-6736(15)60031-9. Epub 2015 Aug 4. Lancet. 2015. PMID: 26466871 Clinical Trial.
-
Tasimelteon for treating non-24-h sleep-wake rhythm disorder.Expert Opin Pharmacother. 2019 Jun;20(9):1065-1073. doi: 10.1080/14656566.2019.1603293. Epub 2019 Apr 16. Expert Opin Pharmacother. 2019. PMID: 30990759
-
Tasimelteon for the treatment of non-24-hour sleep-wake disorder.Drugs Today (Barc). 2015 Jan;51(1):29-35. doi: 10.1358/dot.2015.51.1.2258364. Drugs Today (Barc). 2015. PMID: 25685859 Review.
-
Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals.CNS Drugs. 2016 May;30(5):461-8. doi: 10.1007/s40263-016-0330-y. CNS Drugs. 2016. PMID: 27003694 Review.
-
Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients.CNS Spectr. 2014 Dec;19(6):475-8. doi: 10.1017/S1092852914000637. CNS Spectr. 2014. PMID: 25422900 Review.
Cited by
-
The parent and family impact of CLN3 disease: an observational survey-based study.Orphanet J Rare Dis. 2024 Mar 18;19(1):125. doi: 10.1186/s13023-024-03119-8. Orphanet J Rare Dis. 2024. PMID: 38500130 Free PMC article.
-
Significance of Melatonin in the Regulation of Circadian Rhythms and Disease Management.Mol Neurobiol. 2024 Aug;61(8):5541-5571. doi: 10.1007/s12035-024-03915-0. Epub 2024 Jan 11. Mol Neurobiol. 2024. PMID: 38206471 Review.
-
Melatonin as a Chronobiotic/Cytoprotective Agent in REM Sleep Behavior Disorder.Brain Sci. 2023 May 13;13(5):797. doi: 10.3390/brainsci13050797. Brain Sci. 2023. PMID: 37239269 Free PMC article. Review.
-
Melatonin's Benefits and Risks as a Therapy for Sleep Disturbances in the Elderly: Current Insights.Nat Sci Sleep. 2022 Oct 14;14:1843-1855. doi: 10.2147/NSS.S380465. eCollection 2022. Nat Sci Sleep. 2022. PMID: 36267165 Free PMC article. Review.
-
Melatonin as an Add-On Treatment of COVID-19 Infection: Current Status.Diseases. 2021 Sep 20;9(3):64. doi: 10.3390/diseases9030064. Diseases. 2021. PMID: 34562971 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical